{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:57:10Z","timestamp":1789390630195,"version":"build-2803163510"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Neoadjuvant trastuzumab\/pertuzumab (HP) plus chemotherapy for HER2-positive breast cancer (BC) achieved promising efficacy. The additional cardiotoxicity still existed. Brecan study evaluated the efficacy and safety of neoadjuvant pegylated liposomal doxorubicin (PLD)\/cyclophosphamide and sequential nab-paclitaxel based on HP (PLD\/C\/HP-nabP\/HP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Brecan was a single-arm phase II study. Eligible patients with stages IIA-IIIC HER2-positive BC received 4 cycles of PLD, cyclophosphamide, and HP, followed by 4 cycles of nab-paclitaxel and HP. Definitive surgery was scheduled after 21 days for patients completing treatment or experiencing intolerable toxicity. The primary endpoint was the pathological complete response (pCR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between January 2020 and December 2021, 96 patients were enrolled. Ninety-five (99.0%) patients received 8 cycles of neoadjuvant therapy and all underwent surgery with 45 (46.9%) breast-conserving surgery and 51 (53.1%) mastectomy. The pCR was 80.2% (95%CI, 71.2%-87.0%). Four (4.2%) experienced left ventricular insufficiency with an absolute decline in LVEF (43%-49%). No congestive heart failure and \u2265grade 3 cardiac toxicity occurred. The objective response rate was 85.4% (95%CI, 77.0%-91.1%), including 57 (59.4%) complete responses and 25 (26.0%) partial responses. The disease control rate was 99.0% (95%CI, 94.3%-99.8%). For overall safety, \u2265grade 3 AEs occurred in 30 (31.3%) and mainly included neutropenia (30.2%) and asthenia (8.3%). No treatment-related deaths occurred. Notably, age of &amp;gt;30 (P = .01; OR = 5.086; 95%CI, 1.44-17.965) and HER2 IHC 3+ (P = .02; OR = 4.398; 95%CI, 1.286-15.002) were independent predictors for superior pCR (ClinicalTrials.gov Identifier NCT05346107).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Brecan study demonstrated the encouraging safety and efficacy of neoadjuvant PLD\/C\/HP-nabP\/HP, suggesting a potential therapeutic option in HER2-positive BC.<\/jats:p><\/jats:sec>","DOI":"10.1093\/oncolo\/oyad160","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T13:30:34Z","timestamp":1685539834000},"page":"e15-e24","source":"Crossref","is-referenced-by-count":9,"title":["A Phase II Study of Neoadjuvant PLD\/Cyclophosphamide and Sequential<i>nab<\/i>-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer"],"prefix":"10.1093","volume":"29","author":[{"given":"Ji-Xin","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Thyroid Breast and Vascular Surgery, Xijing Hospital of Air Force Military Medical University , Xi\u2019an 710032 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thyroid Breast and Vascular Surgery, Xijing Hospital of Air Force Military Medical University , Xi\u2019an 710032 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Yu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Thyroid Breast and Vascular Surgery, Xijing Hospital of Air Force Military Medical University , Xi\u2019an 710032 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thyroid Breast and Vascular Surgery, Xijing Hospital of Air Force Military Medical University , Xi\u2019an 710032 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Thyroid Breast and Vascular Surgery, Xijing Hospital of Air Force Military Medical University , Xi\u2019an 710032 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Xin","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Thyroid Breast and Vascular Surgery, Xijing Hospital of Air Force Military Medical University , Xi\u2019an 710032 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Thyroid Breast and Vascular Surgery, Xijing Hospital of Air Force Military Medical University , Xi\u2019an 710032 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Ling","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Thyroid Breast and Vascular Surgery, Xijing Hospital of Air Force Military Medical University , Xi\u2019an 710032 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Dong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Thyroid Breast and Vascular Surgery, Xijing Hospital of Air Force Military Medical University , Xi\u2019an 710032 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Chen","family":"Tie","sequence":"additional","affiliation":[{"name":"Department of Thyroid Breast and Vascular Surgery, Xijing Hospital of Air Force Military Medical University , Xi\u2019an 710032 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thyroid Breast and Vascular Surgery, Xijing Hospital of Air Force Military Medical University , Xi\u2019an 710032 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-Fan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Anhui Medical University , Hefei 230601 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-Lin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thyroid Breast and Vascular Surgery, Xijing Hospital of Air Force Military Medical University , Xi\u2019an 710032 , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"issue":"5","key":"2024010523395852100_CIT0001","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3322\/caac.21634","article-title":"Evolving standards of care and new challenges in the management of HER2-positive breast cancer","volume":"70","author":"Choong","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"4785","key":"2024010523395852100_CIT0002","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science (New York, NY)"},{"issue":"8","key":"2024010523395852100_CIT0003","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2024010523395852100_CIT0004","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"16","key":"2024010523395852100_CIT0005","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","article-title":"Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer","volume":"23","author":"Buzdar","year":"2005","journal-title":"J Clin Oncol"},{"issue":"January-December 2021","key":"2024010523395852100_CIT0006","doi-asserted-by":"crossref","first-page":"17588359211006948","DOI":"10.1177\/17588359211006948","article-title":"Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis","volume":"13","author":"Zhang","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"2024010523395852100_CIT0007","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024010523395852100_CIT0008","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9","key":"2024010523395852100_CIT0009","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"2024010523395852100_CIT0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1158\/1078-0432.CCR-06-1345","article-title":"Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen","volume":"13","author":"Buzdar","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2024010523395852100_CIT0011","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"2024010523395852100_CIT0012","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"2024010523395852100_CIT0013","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/annonc\/mdr024","article-title":"Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM\/2004-05 study","volume":"22","author":"Mart\u00edn","year":"2011","journal-title":"Ann Oncol"},{"issue":"18","key":"2024010523395852100_CIT0014","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.2005.03.8331","article-title":"Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial","volume":"24","author":"Chia","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"2024010523395852100_CIT0015","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/annonc\/mdr519","article-title":"Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial","volume":"23","author":"Rayson","year":"2012","journal-title":"Ann Oncol"},{"issue":"7","key":"2024010523395852100_CIT0016","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/annonc\/mdr519","article-title":"Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial","volume":"23","author":"Rayson","year":"2012","journal-title":"Ann Oncol"},{"issue":"31","key":"2024010523395852100_CIT0017","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"2024010523395852100_CIT0018","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial","volume":"17","author":"Untch","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"2024010523395852100_CIT0019","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10549-010-1047-0","article-title":"A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer","volume":"123","author":"Yardley","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2024010523395852100_CIT0020","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.clbc.2014.12.003","article-title":"Phase II study of neoadjuvant anthracycline-based regimens combined with nanoparticle albumin-bound paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive operable breast cancer","volume":"15","author":"Tanaka","year":"2015","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"2024010523395852100_CIT0021","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3322\/caac.21393","article-title":"Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Giuliano","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2024010523395852100_CIT0022","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12916-018-1233-1","article-title":"Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial","volume":"17","author":"Gavila","year":"2019","journal-title":"BMC Med"},{"issue":"2","key":"2024010523395852100_CIT0023","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"5","key":"2024010523395852100_CIT0024","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0960-9776(03)00106-1","article-title":"A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival","volume":"12","author":"Ogston","year":"2003","journal-title":"Breast (Edinburgh, Scotland)"},{"issue":"16","key":"2024010523395852100_CIT0025","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J Clin Oncol"},{"issue":"31","key":"2024010523395852100_CIT0026","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2024010523395852100_CIT0027","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10549-016-3947-0","article-title":"Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence","volume":"159","author":"Li","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2024010523395852100_CIT0028","doi-asserted-by":"crossref","first-page":"175","DOI":"10.21037\/gs-20-574","article-title":"Clinicopathological characteristics and treatment of young women with breast cancer in China: a nationwide multicenter 10-year retrospective study","volume":"10","author":"Zhang","year":"2021","journal-title":"Gland Surg"},{"issue":"April 2020","key":"2024010523395852100_CIT0029","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/tbcr.2020.03.05","article-title":"CSCO BC guideline: updates for HER2 positive breast cancer in 2020","volume":"1","author":"Li","year":"2020","journal-title":"Transl Breast Cancer Res"},{"issue":"November 2017","key":"2024010523395852100_CIT0030","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.biopha.2017.09.059","article-title":"A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer","volume":"95","author":"Shafei","year":"2017","journal-title":"Biomed Pharmacother"},{"issue":"June 2016","key":"2024010523395852100_CIT0031","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jconrel.2016.04.028","article-title":"Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin","volume":"232","author":"Petersen","year":"2016","journal-title":"J Control Release"},{"issue":"1","key":"2024010523395852100_CIT0032","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41598-020-80415-w","article-title":"Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin","volume":"11","author":"Liu","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"2024010523395852100_CIT0033","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djm252","article-title":"HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials","volume":"100","author":"Gennari","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"2024010523395852100_CIT0034","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"2024010523395852100_CIT0035","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1200\/JCO.18.01842","article-title":"NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69-GeparSepto","volume":"37","author":"Untch","year":"2019","journal-title":"J Clin Oncol"},{"issue":"August 2021","key":"2024010523395852100_CIT0036","doi-asserted-by":"crossref","first-page":"622621","DOI":"10.3389\/fonc.2021.622621","article-title":"Evolving trends in surgical management of breast cancer: an analysis of 30 years of practice changing papers","volume":"11","author":"Keelan","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"2024010523395852100_CIT0037","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10549-017-4653-2","article-title":"Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer","volume":"169","author":"Foldi","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"March 2022","key":"2024010523395852100_CIT0038","doi-asserted-by":"crossref","first-page":"819818","DOI":"10.3389\/fonc.2022.819818","article-title":"Association of HER-2\/CEP17 ratio and HER-2 copy number with pCR rate in HER-2-positive breast cancer after dual-target neoadjuvant therapy with trastuzumab and pertuzumab","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"issue":"44","key":"2024010523395852100_CIT0039","doi-asserted-by":"crossref","first-page":"e27632","DOI":"10.1097\/MD.0000000000027632","article-title":"Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer","volume":"100","author":"Chen","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"40","key":"2024010523395852100_CIT0040","doi-asserted-by":"crossref","first-page":"e30892","DOI":"10.1097\/MD.0000000000030892","article-title":"Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer","volume":"101","author":"Ma","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"2024010523395852100_CIT0041","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.6004\/jnccn.2017.0158","article-title":"Pathologic complete response after neoadjuvant chemotherapy and long-term outcomes among young women with breast cancer","volume":"15","author":"Spring","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"15","key":"2024010523395852100_CIT0042","doi-asserted-by":"crossref","first-page":"13688","DOI":"10.18632\/oncotarget.4051","article-title":"Gene expression in \u201cyoung adult type\u201d breast cancer: a retrospective analysis","volume":"6","author":"Johnson","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"2024010523395852100_CIT0043","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-018-4699-9","article-title":"Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-2013","volume":"169","author":"Shoemaker","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2024010523395852100_CIT0044","doi-asserted-by":"crossref","first-page":"100029","DOI":"10.1016\/j.esmoop.2020.100029","article-title":"Breast cancer in very young women-a multicenter 10-year experience","volume":"6","author":"Eiriz","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"2024010523395852100_CIT0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jmedgenet-2015-103132","article-title":"Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries","volume":"53","author":"Kwong","year":"2016","journal-title":"J Med Genet"},{"issue":"2","key":"2024010523395852100_CIT0046","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10549-012-2158-6","article-title":"Systemic therapy options in BRCA mutation-associated breast cancer","volume":"135","author":"Bayraktar","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"2024010523395852100_CIT0047","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.3390\/ijerph19074260","article-title":"Predicting response to anthracyclines in ovarian cancer","volume":"19","author":"Ferrero","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"January 2018","key":"2024010523395852100_CIT0048","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","article-title":"Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer","volume":"89","author":"Schneeweiss","year":"2018","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"3","key":"2024010523395852100_CIT0049","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/annonc\/mdw610","article-title":"Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial","volume":"28","author":"Loibl","year":"2017","journal-title":"Ann Oncol"},{"issue":"10","key":"2024010523395852100_CIT0050","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/annonc\/mdh393","article-title":"Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer","volume":"15","author":"Chan","year":"2004","journal-title":"Ann Oncol"},{"issue":"3","key":"2024010523395852100_CIT0051","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/1\/e15\/55119263\/oyad160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/1\/e15\/55119263\/oyad160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T15:33:33Z","timestamp":1729524813000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/1\/e15\/7190549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,6,5]]},"published-print":{"date-parts":[[2024,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad160","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,6,5]]}}}